Skip to content

Study · Case report or series · n = 1 · 2026

4 results

Simultaneous bilateral NAION following initiation of high-dose semaglutide: a case report.

Asensio-Sánchez VM, Rodríguez-Espinosa J, Silva-Schultz S, González-Fernández G, Lallana-Serrano S

Archivos de la Sociedad Espanola de Oftalmologia6 Mar 2026

PMID41796736 (opens in a new tab)DOI10.1016/j.oftale.2026.502490 (opens in a new tab)PepBankPUB-41796736
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a 68-year-old man with type 2 diabetes, visual loss began 14 days after he started semaglutide 0.5mg/week and progressed to functional blindness within four weeks.

    In plain wordsIn one man with diabetes, vision loss began 14 days after starting semaglutide and became near-blindness within four weeks.

    Peptide
    Semaglutide
    Outcome
    Not applicableTime to onset of visual loss after starting semaglutide
    Study

    n = 1

    Outcome group
    Adverse events · Eye
    Studied dose
    0.5mg/weekAs given in this study (human).

    Measurements

    Time to onset of visual loss
    14 days
    after starting semaglutide

    Source sentences

    Summary
    Visual loss began 14 days after initiating semaglutide at a relatively high dose (0.5mg/week), progressing to functional blindness within four weeks.
    1 context sentence
    Summary · context
    We report a case of simultaneous bilateral non-arteritic anterior ischemic optic neuropathy (NAION) in a 68-year-old man with poorly controlled type 2 diabetes mellitus and significant hyperopia (+5 diopters).
  2. 02HumanCase report or seriesSafety outcome

    In this man, examination showed bilateral optic disc edema with hemorrhages, exudates, and subretinal fluid after semaglutide was started.

    In plain wordsIn one man who had started semaglutide, eye examination showed swelling and bleeding at the back of both eyes.

    Peptide
    Semaglutide
    Outcome
    Not applicableOptic disc findings on eye examination
    Study

    n = 1

    Outcome group
    Adverse events · Eye
    Studied dose
    0.5mg/weekAs given in this study (human).

    Source sentences

    Summary
    Ophthalmologic examination revealed bilateral optic disc edema with hemorrhages, exudates, and subretinal fluid.
    1 context sentence
    Summary · context
    We report a case of simultaneous bilateral non-arteritic anterior ischemic optic neuropathy (NAION) in a 68-year-old man with poorly controlled type 2 diabetes mellitus and significant hyperopia (+5 diopters).
  3. 03HumanCase report or seriesSafety outcome

    In this man, visual loss persisted despite semaglutide discontinuation and corticosteroid treatment.

    In plain wordsIn one man, vision loss stayed after semaglutide was stopped and steroid treatment was given.

    Peptide
    Semaglutide
    Outcome
    Not applicablePersistence of visual loss after drug discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Eye
    Studied dose
    0.5mg/weekAs given in this study (human).

    Source sentences

    Summary
    Despite drug discontinuation and corticosteroid treatment, visual loss persisted.
    1 context sentence
    Summary · context
    We report a case of simultaneous bilateral non-arteritic anterior ischemic optic neuropathy (NAION) in a 68-year-old man with poorly controlled type 2 diabetes mellitus and significant hyperopia (+5 diopters).
  4. 04HumanCase report or seriesEfficacy outcome

    In this man with poorly controlled type 2 diabetes, glycated hemoglobin decreased after the high dose of semaglutide; the authors advise caution about the size and speed of the fall.

    In plain wordsIn one man with diabetes, a blood sugar marker fell after high-dose semaglutide. The authors urge caution about the size and speed.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlycated hemoglobin after high-dose semaglutide
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.5mg/weekAs given in this study (human).

    Source sentences

    Summary
    Following the high dose of semaglutide, glycated hemoglobin decreased
    1 context sentence
    Summary · context
    We report a case of simultaneous bilateral non-arteritic anterior ischemic optic neuropathy (NAION) in a 68-year-old man with poorly controlled type 2 diabetes mellitus and significant hyperopia (+5 diopters).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.